Viewing Study NCT04580420

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 4:18 AM
Ignite Modification Date: 2026-03-08 @ 1:58 AM
Study NCT ID: NCT04580420
Status: RECRUITING
Last Update Posted: 2025-12-24
First Post: 2020-09-24
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Safety & Efficacy of DCR-PHXC in Patients With PH1 and ESRD
Sponsor: Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Primary Hyperoxaluria Type 1 View
None End Stage Renal Disease View
Keywords:

Keywords

Keyword Brief Keyword Text View
None ESRD View
None PH1 View